Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2008, Vol. 2 Issue (1) : 51-57     DOI: 10.1007/s11684-008-0010-5
|
Antitumor immunity of human SART3 gene vaccine against mouse tumor
HE Yu, YANG Shuhua, LIU Yong, LI Tao
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Download: PDF(320 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  To determine whether squamous cell carcinoma antigen recognized by human T cell 3 (SART3) gene can induce antitumor immunity against tumor cells which express the gene, we constructed mouse tumor cells expressing human SART3 (LM8-SART3) and carried out experiments in vitro/vivo. After subcutaneous injection with SART3 gene vaccine, cytotoxic T lymphocyte (CTL) activity in vitro was measured using Cell Counting Kit-8. As for the in vivo part, C3H mice were divided into several groups. One group was challenged with tumor cells after immunity. Another group was treated with the vaccine after tumor implantation. It was found that human SART3 DNA vaccine can elicit a specific CTL reaction from the mouse splenocytes. After vaccination, tumor occurrence and tumor growth speed was reduced. The vaccine also shows activity in tumor treatment. We conclude that the human SART3 DNA vaccine can induce antitumor ability against tumor cells expressing human SART3 (LM8-SART3) in vitro/vivo which may provide new possibilities in antitumor therapy.
Issue Date: 05 March 2008
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-008-0010-5     OR     http://academic.hep.com.cn/fmd/EN/Y2008/V2/I1/51
1 Tsuda N Murayama K Ishida H Matsunaga K Komiya S Itoh K Yamada A Expression ofa newly defined tumor-rejection antigen SART3 in musculoskeletal tumorsand induction of HLA class I-restricted cytotoxic T lymphocytes bySART3-derived peptidesJ Orthop Res 2001 19(3)346351
2 Catros-Quemener V Bouet F Genetet N Antitumor immunity and cellular cancer therapiesMed Sci (Paris) 2003 19(1)4353
3 Nicodemus C F Smith L M Schultes B C Role of monoclonal antibodies in tumor-specific immunity.Expert Opin Biol Ther 2007 7(3)331343
4 Huang F M Zheng Q X Lv B Bao T Z Cloning andExpression of hB7-1/Sart3 Fusion ProteinHuazhong Keji Daxue Xuebao (Medical edition) 2004 33(2)165168(in Chinese)
5 Uenaka A Nakayama E Analysis of tumor rejectionantigen peptides recognized by specific CTLNippon Rinsho 1996 54(1)242249(in Japanese)
6 Yang D Nakao M Shichijo S Sasatomi T Takasu H Matsumoto H Mori K Hayashi A Yamana H Shirouzu K Itoh K Identificationof a gene coding for a protein possessing shared tumor epitopes capableof inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patientsCancer Res 1999 59(16)40564063
7 Nagamori M Kawaguchi S Murakami M Wada T Nagoya S Yamashita T Inobe M Uede T Intrinsic and extrinsic manipulation of B7/CTLA-4 interactionfor induction of anti-tumor immunity against osteosarcoma cellsAnticancer Res 2002 22(6A)32233227
8 Harada K Yamada A Mine T Kawagoe N Takasu H Itoh K Mousehomologue of the human SART3 gene encoding tumor-rejection antigenJpn J Cancer Res 2000 91(2)239247
9 Hodi F S Dranoff G Combinatorial cancer immunotherapyAdv Immunol 2006 90341368
10 Palena C Abrams S I Schlom J Hodge J W Cancer vaccines:preclinical studies and novel strategiesAdv Cancer Res 2006 95115145
11 Niiya F Nishizaka S Matsunaga K Koufuji K Mori M Katai H Yamana H Itoh K Expression of SART3 tumor-rejection antigen in gastriccancersJpn J Cancer Res 2000 91(3)337342
12 Kawagoe N Shintaku I Yutani S Etoh H Matuoka K Noda S Itoh K Expression of the SART3 tumorrejection antigen in renal cell carcinomaJ Urol 2000 164(6)20902095
13 Suefuji Y Sasatomi T Shichijo S Nakagawa S Deguchi H Koga T Kameyama T Itoh K Expression of SART3 antigen and induction of CTLs by SART3-derivedpeptides in breast cancer patientsBr JCancer 2001 84(7)915919
14 Fukuda K Expressionof the SART3 antigens in oral cancersKurumeMed J 2001 48(1)5558
15 Hersh E M Stopeck A T Advances in the biologicaltherapy and gene therapy of malignant diseaseClin Cancer Res 1997 3(12 Pt 2)26232629
16 Moiseyenko V Imyanitov E Danilova A Danilov A Baldueva I Cell technologies in immunotherapy of cancerAdv Exp Med Biol 2007 601387393
17 Dzierzbicka K Kolodziejczyk A M Adjuvants--essential componentsof new generation vaccinesPostepy Biochem 2006 52(2)204211
18 Jager E Jager D Knuth A Antigen-specific immunotherapy and cancer vaccinesInt J Cancer 2003 106(6)817820
19 Muehlbauer P M Schwartzentruber DJ Cancer vaccinesSemin Oncol Nurs 2003 19(3)206216
20 Soltani M S Belghith Z Gacem H Bchir A Value of vaccinationdata analysis at the district levelEastMediterr Health J 1999 5(3)565571
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed